|
KMID : 1137020180290030040
|
|
Journal of Gynecologic Oncology
2018 Volume.29 No. 3 p.40 ~ p.40
|
|
|
A score system for complete cytoreduction in selected recurrent ovarian cancer patients undergoing secondary cytoreductive surgery: predictors- and nomogram-based analyses
|
|
Bogani Giorgio
Tagliabue Elena
Signorelli Mauro
Ditto Antonino
Martinelli Fabio
Chiappa Valentina
Mosca Lavinia
Sabatucci Ilaria
Maggiore Umberto Leone Roberti
Lorusso Domenica
Raspagliesi Francesco
|
|
|
Abstract
|
|
|
Objective: To test the applicability of the Arbeitsgemeinschaft Gynakologische Onkologie (AGO) and Memorial Sloan Kettering (MSK) criteria in predicting complete cytoreduction (CC) in patients undergoing secondary cytoreductive surgery (SCS) for recurrent ovarian cancer (ROC).
Methods: Data of consecutive patients undergoing SCS were reviewed. The Arbeitsgemeinschaft Gynakologische Onkologie OVARian cancer study group (AGO-OVAR) and MSK criteria were retrospectively applied. Nomograms, based on AGO criteria, MSK criteria and both AGO and MSK criteria were built in order to assess the probability to achieve CC at SCS.
Results: Overall, 194 patients met the inclusion criteria. CC was achieved in 161 (82.9%) patients. According to the AGO-OVAR criteria, we observed that CC was achieved in 87.0% of patients with positive AGO score. However, 45 out of 71 (63.4%) patients who did not fulfilled the AGO score had CC. Similarly, CC was achieved in 87.1%, 61.9% and 66.7% of patients for whom SCS was recommended, had to be considered and was not recommended, respectively. In order to evaluate the predictive value of the AGO-OVAR and MSK criteria we built 2 separate nomograms (c-index: 0.5900 and 0.5989, respectively) to test the probability to achieve CC at SCS. Additionally, we built a nomogram using both the aforementioned criteria (c-index: 0.5857).
Conclusion: The AGO and MSK criteria help identifying patients deserving SCS. However, these criteria might be strict, thus prohibiting a beneficial treatment in patients who do not met these criteria. Further studies are needed to clarify factors predicting CC at SCS.
|
|
|
KEYWORD
|
|
|
Ovarian Neoplasms, Recurrence, Cytoreduction Surgical Procedures
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
    
|
|